-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Society News
-
US FDA Grants Priority Review for Zongertinib for Advanced HER2+ NSCLC
Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients.
-
New Combination Therapies Mean More Options, Challenge Decision-Making
Dr. Susan Scott discusses how findings from the MARIPOSA and FLAURA-2 trials will be incorporated into clinical practice.
-
Experts Share New Insights, Key Updates During Final Plenary Session of the 2024 ACLC
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment.
-
New, Indisputable Data Demonstrate Smoking Cessation Should be Considered a First-Line Therapeutic Intervention for Thoracic Malignancies
Drs. Joelle Fathi and Mahdi Sheikh summarize the growing body of evidence that shows quitting smoking after diagnosis improves survival.
-
Amivantamab-Vmjw Plus Lazertinib Shows Statistically Significant and Clinically Meaningful Improvement in Overall Survival Versus Osimertinib Alone
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer.
-
In Brief for January 22, 2025
FDA issues draft guidance on the use of AI for biological and drug product submissions, China’s NMPA grants priority review for the combination of savolitinib and osimertinib, and nivolumab and hyaluronidase-nvhy receive FDA approval for subcutaneous injection.
-
Emerging Biomarkers Have Potential to Refine Patient Selection, Improve Immunotherapy Strategies
Drs. Marina Chiara Garassino, Sulin Wu, and Faith Abodunrin offer insights from the RELATIVITY-104 and GALAXIES Lung-201 Trials.
-
Future Directions in Lung Cancer Treatment
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives.
-
Research to Watch: Lurbinectedin-Atezolizumab Combination Demonstrates Significant OS, PFS Benefits
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC.
-
BR.31 Trial Falls Short of DFS Primary Endpoint
Prof. Glenwood Goss said adjuvant durvalumab did not improve disease-free survival outcomes following complete resection and optional chemotherapy.